MGTX · CIK 0001735438
MeiraGTx Holdings plc
What MeiraGTx Holdings plc owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
MeiraGTx Holdings plc - Profile
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
- Listed on
- Nasdaq
- Employees
- 403stated 2025
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from MeiraGTx Holdings plc's own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from MeiraGTx Holdings plc Form 10-K for fiscal year 2025 and MeiraGTx Holdings plc Form 10-Q for the quarter ended 30 June 2026, not taken from any single article.
Share price
MGTX
Description
MeiraGTx Holdings plc is a clinical-stage genetic medicines company with principal executive offices in New York, a Cayman Islands exempted company. It develops AAV gene therapies given as small, locally delivered doses and owns its manufacturing, with a GMP viral vector facility in London and a vector, plasmid and quality control campus in Shannon, Ireland. Botaretigene sparoparvovec for X-linked retinitis pigmentosa completed the Phase 3 LUMEOS study, and MeiraGTx bought back full rights from Janssen on 15 April 2026 for $25.0 million upfront plus milestone and royalty obligations. AAV2-hAQP1 for radiation-induced xerostomia received FDA Breakthrough Therapy designation in March 2026, and the pivotal Phase 2 AQUAx2 study completed enrollment in the second quarter of 2026. AAV-GAD for Parkinson's disease is partnered with Hologen, which committed $200.0 million upfront and up to $230.0 million more. Meduretgene parvec for Leber congenital amaurosis 4 was licensed worldwide to Eli Lilly on 7 November 2025 for $75.0 million upfront. There are no approved products. Total revenue was $81.4 million in 2025 against a $114.2 million net loss; first-half 2026 revenue was $321.7 million, mostly the Hologen license, giving net income of $114.4 million. Cash, cash equivalents and restricted cash were $145.4 million at 30 June 2026. MeiraGTx had 403 employees at 31 December 2025.
Who owns MeiraGTx Holdings plc.
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 132 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
132 managers reported a position, together holding 67.4m shares, or 72.8% of the company. The 40 largest are listed. Percentages are of the 92.6m shares outstanding at 8 May 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP G59665102, held by ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, franklin-resources, geode, goldman-sachs, invesco, johnson-johnson, jpmorgan, metlife, morgan-stanley, northern-trust, pnc, prudential-financial, raymond-james, state-street, us-bancorp, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.